Mexico buys oral treatment against COVID-19 from Pfizer
Time to Read: 1 minute
The treatment reduces the risk of hospitalization or death by 89%, when started within three days of the onset of symptoms.
The Mexican government announced that it has signed a purchase agreement for Pfizer's oral antiviral therapy against COVID-19, called Paxlovid .
The contract contemplates the acquisition of 300,000 oral treatments that have already begun to arrive in the country, which was approved by the Federal Commission for the Protection against Sanitary Risks ( Cofepris ) last January.
The treatment includes nirmatrelvir, which is a protease inhibitor that was specifically designed to block the activity of SARS-CoV-2 protease 3CL, an enzyme that the coronavirus needs to replicate.
The president of the laboratory, Constanza Losada , pointed out that ending the effects of the pandemic is everyone's task, so this reflects the objective of continuing to seek the well-being of people.
“This agreement helps us to continue working hand in hand with the Government of Mexico and thus achieve our shared goal of addressing this public health crisis,” the directive said.
The results show that this treatment reduces the risk of hospitalization or death by 89% , when it is started within three days after the onset of symptoms, and by 88%, when it is started within the fourth to fifth day after the onset. of symptoms compared to placebo.
To date, Pfizer has supplied more than 26.2 million oral treatments against COVID-19 to 41 countries.
Currently in Mexico children between 5 and 11 years of age are being vaccinated and boosters are being given in various parts of the country for older adults, adults and young people.